3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Breast
1
Conditions
Glioblastoma
5
Prostatic Neoplasms
4
Glioma
4
Lung Neoplasms
3
Epstein-Barr Virus Infections
3
Astrocytoma
3
Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Cytomegalovirus Infections
2
Breast Neoplasms
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Stomatitis
1
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Mycosis Fungoides
1
Multiple Myeloma
1
Interventions
Paclitaxel
326
Carboplatin
318
Bevacizumab
167
Gemcitabine
106
pembrolizumab
100
liposomal doxorubicin
100
Cyclophosphamide
94
Topotecan
93
Cisplatin
89
olaparib
86
niraparib
60
Docetaxel
56
Taxes
52
Doxorubicin
50
Drug Therapy
42
fludarabine
39
Filgrastim
39
Nivolumab
37
Etoposide
32
Specimen Handling
31
Magnetic Resonance Spectroscopy
29
Immunoglobulin G
27
Disulfides
27
Peripheral Blood Stem Cell Transplantation
26
Albumin-Bound Paclitaxel
25
durvalumab
24
aldesleukin
24
Hyperthermic Intraperitoneal Chemotherapy
24
Oxaliplatin
23
Biopsy
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Ovarian Neoplasms
×
Valacyclovir
×
Clear all
NCT01997190
2023-08-25
MpeTK01
Candel Therapeutics, Inc.
Phase 1
Completed
19 enrolled